Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in Transplantation

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    July 2018
  1. GONZALEZ-DIEGUEZ ML, Vidal DV, Mendoza Pacas GE, Houghton RF, et al
    TACROLIMUS INDUCED CHOLESTATIC HEPATITIS IN A PATIENT WITH LIVER TRANSPLANT.
    Transplantation. 2018 Jul 3. doi: 10.1097/TP.0000000000002332.
    PubMed     Text format    


  2. SAGESHIMA J, Troppmann C, McVicar JP, Santhanakrishnan C, et al
    Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.
    Transplantation. 2018;102:1179-1187.
    PubMed     Text format     Abstract available


  3. ANKCORN MJ, Ijaz S, Poh J, Elsharkawy AM, et al
    Toward Systematic Screening for Persistent Hepatitis E Virus Infections in Transplant Patients.
    Transplantation. 2018;102:1139-1147.
    PubMed     Text format     Abstract available


    June 2018
  4. BOWRING MG, Kucirka LM, Massie AB, Ishaque T, et al
    Changes in utilization and discard of HCV-antibody positive deceased-donor kidneys in the era of direct-acting antiviral therapy.
    Transplantation. 2018 Jun 13. doi: 10.1097/TP.0000000000002323.
    PubMed     Text format     Abstract available


    May 2018
  5. TUCCI A, Rizza S, Cocchis D, Martini S, et al
    Early and late hepatitis B reactivation following IFN- or DAA-based therapy of recurrent hepatitis C in anti-HBc-positive liver transplant recipients.
    Transplantation. 2018 May 2. doi: 10.1097/TP.0000000000002241.
    PubMed     Text format    


    April 2018
  6. JEON JW, Kim SM, Cho H, Baek CH, et al
    Presence of hepatitis B surface antibody in addition to hepatitis B core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation.
    Transplantation. 2018 Apr 5. doi: 10.1097/TP.0000000000002173.
    PubMed     Text format     Abstract available


    March 2018
  7. MALLET V, Sberro-Soussan R, Roque-Afonso AM, Vallet-Pichard A, et al
    Transmission of hepatitis E virus with plasma exchange in kidney-transplant recipients: a retrospective cohort study.
    Transplantation. 2018 Mar 20. doi: 10.1097/TP.0000000000002185.
    PubMed     Text format     Abstract available


  8. WEDEMEYER H
    E-xchange: Hepatitis E and the risk of plasma products for organ transplant recipients.
    Transplantation. 2018 Mar 20. doi: 10.1097/TP.0000000000002186.
    PubMed     Text format    


    February 2018
  9. FARIA LC, Terrabuio DRB, Leblebicioglu H, Huprikar S, et al
    Viral Hepatitis Recommendations for Solid-Organ Transplant Recipients and Donors.
    Transplantation. 2018;102.
    PubMed     Text format    


    January 2018
  10. MCCAULEY M, Mussell A, Goldberg D, Sawinski D, et al
    Race, Risk, and Willingness of End-stage Renal Disease Patients Without Hepatitis C (HCV) to Accept an HCV-infected Kidney Transplant.
    Transplantation. 2018 Jan 18. doi: 10.1097/TP.0000000000002099.
    PubMed     Text format     Abstract available


  11. LIM MA, Kamili S, Cohen J, Green-Montfort T, et al
    Hepatitis E Virus Infection in Kidney Transplant Patients: A Single-center Study.
    Transplantation. 2018 Jan 11. doi: 10.1097/TP.0000000000002071.
    PubMed     Text format    


    November 2017
  12. TROTTER PB, Summers DM, Ushiro-Lumb I, Robb M, et al
    Use of organs from hepatitis C virus positive donors for uninfected recipients: a potential cost-effective approach to save lives?
    Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002033.
    PubMed     Text format     Abstract available


  13. AGARWAL N, Davis RJ, Gracey DM, Wong G, et al
    Detection of Hepatitis C antibodies without viral transmission in Hepatitis C negative recipients receiving kidneys from Hepatitis C positive donors treated with Direct Acting Anti-Viral Therapy.
    Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002034.
    PubMed     Text format    


  14. HOLSCHER CM, Durand CM, Desai NM
    Expanding the Use of Organs from Hepatitis C-Viremic Donors: The Evidence Continues to Build.
    Transplantation. 2017 Nov 22. doi: 10.1097/TP.0000000000002032.
    PubMed     Text format    


  15. KAMAR N, Del Bello A, Izopet J
    Should persistent hepatitis E virus replication in transplant patients be tolerated?
    Transplantation. 2017 Nov 10. doi: 10.1097/TP.0000000000001994.
    PubMed     Text format    


    October 2017
  16. HEO NY, Mannalithara A, Kim D, Udompap P, et al
    Long-term Patient and Graft Survival of Kidney Transplant Recipients with Hepatitis C Virus Infection in the United States.
    Transplantation. 2017 Oct 3. doi: 10.1097/TP.0000000000001953.
    PubMed     Text format     Abstract available


    September 2017
  17. RADHAKRISHNAN K, Chi A, Quan DJ, Roberts JP, et al
    Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients.
    Transplantation. 2017;101:2079-2082.
    PubMed     Text format     Abstract available


    August 2017
  18. ANTONINI TM, Coilly A, Rossignol E, Fougerou-Leurent C, et al
    Sofosbuvir-based Regimens in HIV/HCV Coinfected Patients after Liver Transplantation: Results from the ANRS CO23 CUPILT Study.
    Transplantation. 2017 Aug 24. doi: 10.1097/TP.0000000000001928.
    PubMed     Text format     Abstract available


  19. CHOLANKERIL G, Li AA, Yoo ER, Ahmed A, et al
    Direct-Acting Antiviral Therapy and Improvement in Graft Survival of Hepatitis C Liver Transplant Recipients.
    Transplantation. 2017 Aug 24. doi: 10.1097/TP.0000000000001926.
    PubMed     Text format    


  20. GARCIA CR, Acosta LF, Mei X, Berger J, et al
    Liver Transplantation for the Treatment of Complicated Iatrogenic Biliary Injuries: A National Review from the UNOS Dataset.
    Transplantation. 2017 Aug 22. doi: 10.1097/TP.0000000000001922.
    PubMed     Text format     Abstract available


  21. ABAALKHAIL F, Elsiesy H, Elbeshbeshy H, Shawkat M, et al
    Treatment of Patients With Hepatitis C Virus infection (Genotype 4) With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
    Transplantation. 2017 Aug 9. doi: 10.1097/TP.0000000000001907.
    PubMed     Text format     Abstract available


  22. MCPHERSON S, Elsharkawy AM, Ankcorn M, Ijaz S, et al
    Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation.
    Transplantation. 2017 Aug 9. doi: 10.1097/TP.0000000000001908.
    PubMed     Text format     Abstract available


    July 2017
  23. FUNG J, Wong T, Chok K, Chan A, et al
    Oral nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B with Preexisting rt204 Mutation.
    Transplantation. 2017 Jul 21. doi: 10.1097/TP.0000000000001883.
    PubMed     Text format     Abstract available


  24. WALLER KMJ, Wyburn KR, Shackel NA, O'Leary MJ, et al
    Hepatitis transmission risk in kidney transplantation (the HINT study): a cross-sectional survey of transplant clinicians in Australian and New Zealand.
    Transplantation. 2017 Jul 21. doi: 10.1097/TP.0000000000001885.
    PubMed     Text format     Abstract available


  25. PRUETT TL, Clark MA, Taranto SE
    Deceased Organ Donors and PHS Risk Identification: Impact on Organ Usage and Outcomes.
    Transplantation. 2017;101:1670-1678.
    PubMed     Text format     Abstract available


  26. VOLK ML, Wilk AR, Wolfe C, Kaul DR, et al
    The "PHS Increased Risk" Label Is Associated With Nonutilization of Hundreds of Organs per Year.
    Transplantation. 2017;101:1666-1669.
    PubMed     Text format     Abstract available


    June 2017
  27. MASUTANI K, Omoto K, Okumi M, Okabe Y, et al
    Incidence of Hepatitis B Viral Reactivation After Kidney Transplantation With Low-dose Rituximab Administration.
    Transplantation. 2017 Jun 29. doi: 10.1097/TP.0000000000001870.
    PubMed     Text format     Abstract available


    May 2017

  28. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study: Erratum.
    Transplantation. 2017;101:e193.
    PubMed     Text format    


  29. SINGH N, Dies D, Samant H
    Hepatitis C-Positive Kidney Transplant Recipients-When Is The Best Time to Treat With Direct-Acting Antiviral Agents?
    Transplantation. 2017;101:e192.
    PubMed     Text format    


  30. TERRAULT NA, Berenguer M, Strasser SI, Gadano A, et al
    International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.
    Transplantation. 2017;101:956-967.
    PubMed     Text format    


  31. TERRAULT NA, McCaughan GW, Curry MP, Gane E, et al
    International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.
    Transplantation. 2017;101:945-955.
    PubMed     Text format    


  32. TAPPER EB, Afdhal NH, Curry MP
    Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C.
    Transplantation. 2017;101:933-937.
    PubMed     Text format     Abstract available


    April 2017
  33. MAZZOLA A, Minh MT, Charlotte F, Hdjii A, et al
    Chronic hepatitis E viral infection after liver transplantation: a regression of fibrosis following antiviral therapy.
    Transplantation. 2017 Apr 4. doi: 10.1097/TP.0000000000001766.
    PubMed     Text format     Abstract available


  34. MARTIN MT, Koppe S
    Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis.
    Transplantation. 2017 Apr 3. doi: 10.1097/TP.0000000000001758.
    PubMed     Text format     Abstract available


    March 2017
  35. TERRAULT N, Berenguer M, Strasser S, Gadano A, et al
    International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001704.
    PubMed     Text format    


  36. TERRAULT NA, McCaughan GW, Curry MP, Gane E, et al
    International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001708.
    PubMed     Text format    


  37. ARONSOHN A
    Timing is Everything: Managing Hepatitis C in Liver Transplant Candidates.
    Transplantation. 2017 Mar 1. doi: 10.1097/TP.0000000000001703.
    PubMed     Text format    


    February 2017
  38. VERNA EC, Brown RS Jr
    HCV Antiviral Therapy In Liver Transplant Candidates and Recipients with Renal Insufficiency.
    Transplantation. 2017 Feb 16. doi: 10.1097/TP.0000000000001688.
    PubMed     Text format     Abstract available


  39. SANTOS AH JR, Casey MJ, Xuerong W, Womer KL, et al
    Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States.
    Transplantation. 2017;101:377-386.
    PubMed     Text format     Abstract available


    January 2017
  40. HIRATA Y, Yoshizawa A, Egawa H, Ueda D, et al
    Impact of Antibodies that React with Liver Tissue and Donor-specific anti-HLA Antibodies in Pediatric Idiopathic Posttransplantation Hepatitis.
    Transplantation. 2017 Jan 23. doi: 10.1097/TP.0000000000001653.
    PubMed     Text format     Abstract available


  41. VINAIXA C, Strasser SI, Berenguer M
    DISEASE REVERSIBILITY IN PATIENTS WITH POSTHEPATITIS C CIRRHOSIS: IS THE POINT OF NO RETURN THE SAME BEFORE AND AFTER LIVER TRANSPLANTATION? A REVIEW.
    Transplantation. 2017 Jan 6. doi: 10.1097/TP.0000000000001633.
    PubMed     Text format     Abstract available



  42. Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation: Erratum.
    Transplantation. 2017;101:e40.
    PubMed     Text format    


    December 2016
  43. DEBES JD, de Knegt RJ, Boonstra A
    The path to cancer, and back: Immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals.
    Transplantation. 2016 Dec 30. doi: 10.1097/TP.0000000000001623.
    PubMed     Text format     Abstract available


  44. LUBETZKY M, Chun S, Joelson A, Coco M, et al
    Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients with Directly Acting Antiviral Agents.
    Transplantation. 2016 Dec 22. doi: 10.1097/TP.0000000000001618.
    PubMed     Text format     Abstract available


  45. WERNER JM, Adenugba A, Protzer U
    Immune reconstitution following HCV clearance with direct antiviral agents: potential consequences for patients with HCC?
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  46. SALAZAR J, Saxena V, Kahn JG, Roberts JP, et al
    Cost-Effectiveness of Direct-Acting Anti-viral Treatment in Hepatitis C-infected Liver Transplant Candidates with Compensated Cirrhosis and Hepatocellular Carcinoma.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  47. CARRILLO CF, Crespo G, de la Revilla J, Castells L, et al
    Successful continuation of HCV treatment following liver transplantation.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  48. CROOME KP, Lee DD, Keaveny AP, Taner CB, et al
    Improving National Results in Liver Transplantation Using Grafts From Donation After Cardiac Death Donors.
    Transplantation. 2016;100:2640-2647.
    PubMed     Text format     Abstract available


    November 2016
  49. BARBIER L, Cesaretti M, Dondero F, Cauchy F, et al
    Liver Transplantation With Older Donors: A Comparison With Younger Donors in a Context of Organ Shortage.
    Transplantation. 2016;100:2410-2415.
    PubMed     Text format     Abstract available


    September 2016
  50. ELFEKI M, Abou Mrad R, Modaresi Esfeh J, Zein N, et al
    Sofosbuvir/Ledipasvir without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence after Liver Transplantation: Two-Center Experience.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


    August 2016
  51. EISENBERGER U, Guberina H, Willuweit K, Bienholz A, et al
    Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  52. D S, N P, B A, Rd B, et al
    Use of HCV+ donors does not affect HCV clearance with directly acting antiviral therapy but shortens the wait time to kidney transplantation.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  53. TAPPER EB, Hughes MS, Buti M, Dufour JF, et al
    The optimal timing of hepatitis C therapy in transplant eligible patients with Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


    July 2016
  54. SAWINSKI D, Lee DH, Doyle AM, Blumberg EA, et al
    Successful Posttransplant Treatment of Hepatitis C with Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


    April 2016
  55. BRAUN HJ, Dodge JL, Roll GR, Freise CE, et al
    Impact of Graft Selection on Donor and Recipient Outcomes After Living Donor Liver Transplantation.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


    March 2016
  56. DE SIMONE P, Romagnoli R, Tandoi F, Carrai P, et al
    Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  57. ADDOLORATO G, Bataller R, Burra P, DiMartini A, et al
    Liver Transplantation for Alcoholic Liver Disease.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  58. FAISAL N, Bilodeau M, Aljudaibi B, Hirsch G, et al
    Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
    Transplantation. 2016.
    PubMed     Text format     Abstract available


  59. WATANABE M, Lundgren T, Saito Y, Cerami A, et al
    A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.
    Transplantation. 2016;100:554-62.
    PubMed     Text format     Abstract available


    February 2016
  60. WERNER JM, Vermehren J
    New HCV Therapies and Liver Transplantation.
    Transplantation. 2016;100:260-1.
    PubMed     Text format    


    December 2015
  61. TANIMINE N, Tanaka Y, Abe T, Piao J, et al
    Functional Behavior of NKp46-Positive Intrahepatic Natural Killer Cells Against Hepatitis C Virus Reinfection After Liver Transplantation.
    Transplantation. 2015.
    PubMed     Text format     Abstract available


  62. ABERG F, Nordin A, Toivonen L, Isoniemi H, et al
    Early Predictors of Long-term Outcomes of HCV-Negative Liver Transplant Recipients Having Survived the First Postoperative Year.
    Transplantation. 2015.
    PubMed     Text format     Abstract available


    October 2015
  63. EDMUNDS C, Ekong UD
    Autoimmune Liver Disease Post Liver Transplantation-A Summary and Proposed Areas for Future Research.
    Transplantation. 2015.
    PubMed     Text format     Abstract available


    July 2015
  64. LOCKE JE, Durand C, Reed RD, MacLennan PA, et al
    Long-Term Outcomes After Liver Transplantation Among Human Immunodeficiency Virus-Infected Recipients.
    Transplantation. 2015.
    PubMed     Text format     Abstract available


    June 2015
  65. SHAPIRO AM
    Donor-Specific Antibody in Pediatric Liver Transplantation-Identifying a Tree by its Fruit.
    Transplantation. 2015.
    PubMed     Text format    


  66. WOZNIAK LJ, Hickey MJ, Venick RS, Vargas JH, et al
    Donor-Specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.
    Transplantation. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: